Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 15 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00694590Phase 1
- A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00676871Phase 1/2
- Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantTerminatedNCT00674427Phase 1
- Phase 1 Study of Terameprocol (EM-1421) in Patients With LeukemiaTerminatedNCT00664677Phase 1
- Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic LeukemiaTerminatedNCT00646165Phase 1
- Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT00645606Phase 3
- Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00640523Phase 2
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00634881Phase 1/2
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00628238Phase 2
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
- Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's LymphomaCompletedNCT00614042Phase 1
- Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT00612612Phase 1
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLLCompletedNCT00603668Phase 1/2
- A Phase I/II Study of GX15-070MS in Untreated CLLCompletedNCT00600964Phase 1
- Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Status unknownNCT00598624Phase 2
- Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL PatientsTerminatedNCT00596336Phase 2
- Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00593944Phase 1
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLActive, not recruitingNCT00586391Phase 1
- Investigation of the Cylex® ImmuKnow® AssayCompletedNCT00569842
- A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of ResponseCompletedNCT00565981Phase 2
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPCompletedNCT00564512Phase 3
- Oral Valganciclovir Versus ValacyclovirCompletedNCT00562770Phase 2
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedNCT00562224Phase 1
- Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL PatientsCompletedNCT00559624Phase 1/2
- Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia PatientsTerminatedNCT00558961Phase 1/2
- High-dose Methylprednisolone and Rituximab in High Risk B-CLLCompletedNCT00558181Phase 2
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
- Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
- Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin LymphomaTerminatedNCT00538187Phase 1
- Phase III Study Treatment of CLL B and CCompletedNCT00535912Phase 3
- HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic LeukemiaTerminatedNCT00524667Phase 2
- Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic LeukemiaCompletedNCT00514696Phase 2
- Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic MalignanciesTerminatedNCT00513318
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic AnemiaCompletedNCT00513175
- Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell MalignanciesCompletedNCT00504972Phase 1
- R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT00504491Phase 2
- Genetic Study of Chronic Lymphocytic Leukemia FamiliesStatus unknownNCT00503256
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
- A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00496132Phase 1/2
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaWithdrawnNCT00485966Phase 2
- Kinetic Biomarker for Chronic Lymphocytic Leukemia PrognosisCompletedNCT00481858
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.CompletedNCT00466895Phase 1
- Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Active, not recruitingNCT00466531Phase 1/2
- Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)CompletedNCT00464633Phase 2
- Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor CellsCompletedNCT00458679Phase 1
- Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete RemissionCompletedNCT00458523Phase 2
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid MalignanciesCompletedNCT00446342Phase 1
- Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationCompletedNCT00442130Phase 1
- A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLLCompletedNCT00435084Phase 1/2
- A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00431873Phase 2
- Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine GenerationCompletedNCT00428233Phase 1
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1
- Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaTerminatedNCT00416910Phase 3
- A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid MalignanciesCompletedNCT00406809Phase 1/2
- Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00391066Phase 2
- Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00377104Phase 1
- Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic LeukemiaCompletedNCT00366418Phase 1
- Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte LeukemiaTerminatedNCT00360776Phase 2
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)CompletedNCT00344825
- Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLLTerminatedNCT00344786Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT00343447Phase 2
- Allogeneic Stem Cell Transplantation in Chronic Lymphocytic LeukemiaStatus unknownNCT00337519Phase 2
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT00337246Phase 2
- Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic LeukemiaStatus unknownNCT00336206Not applicable
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1
- AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00321724Phase 2
- Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLLTerminatedNCT00319930Phase 1
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)CompletedNCT00309881Phase 2
- VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative DisordersCompletedNCT00304005Phase 1/2
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)TerminatedNCT00302861Phase 1/2
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
- A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 DeletionCompletedNCT00292760Phase 2
- Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00290004Phase 1/2
- Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT00289549Phase 2
- Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00286780Phase 2
- SPC2996 in Chronic Lymphocytic LeukaemiaCompletedNCT00285103Phase 1/2
- A Safety Study in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00283101Phase 1/2
- Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's MacroglobulinemiaCompletedNCT00281983Phase 1/2
- Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT00281892Phase 3
- Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaCompletedNCT00278213Phase 2
- Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic LeukemiaCompletedNCT00276848Phase 3
- Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic LeukemiaCompletedNCT00276809Phase 2
- Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesCompletedNCT00275431Phase 2
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00275054Phase 3
- Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic LeukemiaCompletedNCT00275015Phase 2
- Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00274989Phase 2
- Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous FludarabineCompletedNCT00274976Phase 2